IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation - Concepedia

Concepedia

Publication | Open Access

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

DOI Full Paper Access

15

Citations

41

References

2023

Year

Elisa A. Rozeman, Judith M. Versluis, Karolina Sikorska, Esmée P. Hoefsmit, Petros Dimitriadis, Disha Rao, Ruben Lacroix, Lindsay G. Grijpink-Ongering, Marta López‐Yurda, Birthe C. Heeres,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02625337.

References

	Year	Citations

Page 1